- Home
- SIGA vs CTMX Comparison
SIGA vs CTMX Comparison
Compare SIGA & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIGA
- CTMX
- Stock Information
- Founded
- SIGA 1995
- CTMX 2008
- Country
- SIGA United States
- CTMX United States
- Employees
- SIGA N/A
- CTMX N/A
- Industry
- SIGA Biotechnology: Pharmaceutical Preparations
- CTMX Biotechnology: Pharmaceutical Preparations
- Sector
- SIGA Health Care
- CTMX Health Care
- Exchange
- SIGA Nasdaq
- CTMX Nasdaq
- Market Cap
- SIGA 515.1M
- CTMX 544.2M
- IPO Year
- SIGA 1997
- CTMX 2015
- Fundamental
- Price
- SIGA $8.28
- CTMX $3.37
- Analyst Decision
- SIGA
- CTMX Strong Buy
- Analyst Count
- SIGA 0
- CTMX 5
- Target Price
- SIGA N/A
- CTMX $5.30
- AVG Volume (30 Days)
- SIGA 479.2K
- CTMX 4.4M
- Earning Date
- SIGA 11-06-2025
- CTMX 11-06-2025
- Dividend Yield
- SIGA 7.11%
- CTMX N/A
- EPS Growth
- SIGA N/A
- CTMX 263.20
- EPS
- SIGA 1.14
- CTMX 0.49
- Revenue
- SIGA $179,639,422.00
- CTMX $141,100,000.00
- Revenue This Year
- SIGA N/A
- CTMX N/A
- Revenue Next Year
- SIGA $115.06
- CTMX N/A
- P/E Ratio
- SIGA $7.27
- CTMX $6.85
- Revenue Growth
- SIGA 3.86
- CTMX 18.01
- 52 Week Low
- SIGA $4.95
- CTMX $0.40
- 52 Week High
- SIGA $9.62
- CTMX $3.49
- Technical
- Relative Strength Index (RSI)
- SIGA 46.70
- CTMX 75.08
- Support Level
- SIGA $8.15
- CTMX $3.11
- Resistance Level
- SIGA $9.29
- CTMX $3.39
- Average True Range (ATR)
- SIGA 0.34
- CTMX 0.24
- MACD
- SIGA -0.11
- CTMX 0.08
- Stochastic Oscillator
- SIGA 24.62
- CTMX 88.52
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.